BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy...
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts. On June 9, BofA analyst Tazeen Ahmad reiterated a ‘Buy’ rating on the...
Tag: Ascendis Pharma
2 results found
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia...
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon...
